Xinguang Bio key facts
- Manufacturer of biopharmaceutical devices intended for therapeutic and diagnostic application purpose.
- It has raised $2.9M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, Empower Investment, Shanghai Highpower Industrial, HiMed Fund, Joyin Incubator — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Xinguang Bio: the Monday email on marks, rounds and moves
Xinguang Bio funding rounds
No funding rounds for Xinguang Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Xinguang Bio investors
7 investors are on record for Xinguang Bio, including Johnson & Johnson Innovation - JLABS, Empower Investment, Shanghai Highpower Industrial and HiMed Fund.
About Xinguang Bio
Manufacturer of biopharmaceutical devices intended for therapeutic and diagnostic application purpose. The company uses enzymes to efficiently, rapidly, and selectively remove harmful molecules from blood, plasma, and dialysis effluents, enabling patients to have an alternative treatment for refractory metabolic diseases, cancer, and liver and kidney malfunction..
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 3
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Xinguang Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.